Very excited to share the latest work of the team @opentargets.org. If you are interested in #targetdiscovery and #genetics check out the latest release of the Open Targets Platform.
Open Targets Platform 25.03 is finally here! 🌼
This update brings in variant, study, and credible set information, uniting the Open Targets Platform and Open Targets Genetics into a one-stop shop for human genetic and target discovery information.
blog.opentargets.org/open-targets...
This update brings in variant, study, and credible set information, uniting the Open Targets Platform and Open Targets Genetics into a one-stop shop for human genetic and target discovery information.
blog.opentargets.org/open-targets...
March 20, 2025 at 9:13 AM
Very excited to share the latest work of the team @opentargets.org. If you are interested in #targetdiscovery and #genetics check out the latest release of the Open Targets Platform.
!!! Less than 2 weeks left to register !!! Join us in Milan for the 2nd European Cancer Dependency Map Symposium, taking place on 20 November 2025 at Human Technopole
Cancer functional genomics; CRISPR-based screening;
AIdriven targetDiscovery and drug development
humantechnopole.it/en/trainings...
Cancer functional genomics; CRISPR-based screening;
AIdriven targetDiscovery and drug development
humantechnopole.it/en/trainings...
October 21, 2025 at 10:08 AM
!!! Less than 2 weeks left to register !!! Join us in Milan for the 2nd European Cancer Dependency Map Symposium, taking place on 20 November 2025 at Human Technopole
Cancer functional genomics; CRISPR-based screening;
AIdriven targetDiscovery and drug development
humantechnopole.it/en/trainings...
Cancer functional genomics; CRISPR-based screening;
AIdriven targetDiscovery and drug development
humantechnopole.it/en/trainings...
We will be at #AACR25 in Chicago, USA
Poster presentation: "A compressed genome-wide CROP-Seq screen to dissect the polarization of THP-1-derived macrophages"
🎯 When: Sunday, April 27 from 2.00 - 5.00 PM EST
🎯 Poster: LB043, Section 52
myllia.com
#CRISPR #scRNASeq #TargetDiscovery #FGX
Poster presentation: "A compressed genome-wide CROP-Seq screen to dissect the polarization of THP-1-derived macrophages"
🎯 When: Sunday, April 27 from 2.00 - 5.00 PM EST
🎯 Poster: LB043, Section 52
myllia.com
#CRISPR #scRNASeq #TargetDiscovery #FGX
April 8, 2025 at 2:14 PM
We will be at #AACR25 in Chicago, USA
Poster presentation: "A compressed genome-wide CROP-Seq screen to dissect the polarization of THP-1-derived macrophages"
🎯 When: Sunday, April 27 from 2.00 - 5.00 PM EST
🎯 Poster: LB043, Section 52
myllia.com
#CRISPR #scRNASeq #TargetDiscovery #FGX
Poster presentation: "A compressed genome-wide CROP-Seq screen to dissect the polarization of THP-1-derived macrophages"
🎯 When: Sunday, April 27 from 2.00 - 5.00 PM EST
🎯 Poster: LB043, Section 52
myllia.com
#CRISPR #scRNASeq #TargetDiscovery #FGX
Out now @arvoinfo.bsky.social journal IOVS:
Functional validation of AMD genes identified through integrative multi-omics analyses:
iovs.arvojournals.org/article.aspx...
#labintheloop #diseasebiology #targetdiscovery #multiomics #AI #techbio #ophthalmology
Functional validation of AMD genes identified through integrative multi-omics analyses:
iovs.arvojournals.org/article.aspx...
#labintheloop #diseasebiology #targetdiscovery #multiomics #AI #techbio #ophthalmology
July 8, 2025 at 1:49 PM
Out now @arvoinfo.bsky.social journal IOVS:
Functional validation of AMD genes identified through integrative multi-omics analyses:
iovs.arvojournals.org/article.aspx...
#labintheloop #diseasebiology #targetdiscovery #multiomics #AI #techbio #ophthalmology
Functional validation of AMD genes identified through integrative multi-omics analyses:
iovs.arvojournals.org/article.aspx...
#labintheloop #diseasebiology #targetdiscovery #multiomics #AI #techbio #ophthalmology
Setting up a target analysis usually means building the pipeline before the real question. Disease Atlas by Euretos is already integrated and harmonised across 34,000 diseases and disorders. Upload a gene set and evaluate in the same session, not after a build. #TargetDiscovery
September 25, 2026 at 7:02 AM
Setting up a target analysis usually means building the pipeline before the real question. Disease Atlas by Euretos is already integrated and harmonised across 34,000 diseases and disorders. Upload a gene set and evaluate in the same session, not after a build. #TargetDiscovery
Finding a candidate, checking it holds up, and choosing the next disease are usually three tools and three context switches. Disease Atlas by Euretos runs all three from one foundation, so you keep the thread as the question changes shape. #TargetDiscovery
September 24, 2026 at 7:02 AM
Finding a candidate, checking it holds up, and choosing the next disease are usually three tools and three context switches. Disease Atlas by Euretos runs all three from one foundation, so you keep the thread as the question changes shape. #TargetDiscovery
💡 Most drug discovery tools look at biology in segments. Hyper-C is built to see diseases and drugs play out across systems. Explore Hyper-C's core components at 📍 delta4.ai/hyper-c
#DrugDiscovery #SystemsBiology #Biotech #TargetDiscovery #BiomarkerID #indicationExpansion
#DrugDiscovery #SystemsBiology #Biotech #TargetDiscovery #BiomarkerID #indicationExpansion
April 2, 2026 at 7:04 PM
💡 Most drug discovery tools look at biology in segments. Hyper-C is built to see diseases and drugs play out across systems. Explore Hyper-C's core components at 📍 delta4.ai/hyper-c
#DrugDiscovery #SystemsBiology #Biotech #TargetDiscovery #BiomarkerID #indicationExpansion
#DrugDiscovery #SystemsBiology #Biotech #TargetDiscovery #BiomarkerID #indicationExpansion
Once a target works in one disease, which disease is next? Disease Atlas by Euretos scores a known target across indications on causal evidence. TYK2 is validated in psoriasis; aim the same evidence at lupus and the biology concurs (concordant, p around 0.006). #TargetDiscovery
September 22, 2026 at 7:02 AM
Once a target works in one disease, which disease is next? Disease Atlas by Euretos scores a known target across indications on causal evidence. TYK2 is validated in psoriasis; aim the same evidence at lupus and the biology concurs (concordant, p around 0.006). #TargetDiscovery
The Digital Proteome is a multi-species protein expression atlas designed to support #TargetDiscovery and validation. It enables a richer understanding of target accessibility, off-target liabilities, and pathway coverage.
👉Download the poster to learn more: biognosys.com/resources/di...
👉Download the poster to learn more: biognosys.com/resources/di...
December 11, 2025 at 2:54 PM
The Digital Proteome is a multi-species protein expression atlas designed to support #TargetDiscovery and validation. It enables a richer understanding of target accessibility, off-target liabilities, and pathway coverage.
👉Download the poster to learn more: biognosys.com/resources/di...
👉Download the poster to learn more: biognosys.com/resources/di...
This study shows Kae alleviates #Arthritis in mice by balancing #Treg/#Th17 via the #miR34a/#Foxp3 axis, highlighting #therapeutic potential for #RA and #Immune #Homeostasis. #medsky
Full article here: doi.org/10.1007/s115...
#TargetDiscovery #TherapeuticTargets #DrugDevelopment
Full article here: doi.org/10.1007/s115...
#TargetDiscovery #TherapeuticTargets #DrugDevelopment
April 3, 2026 at 2:30 PM
This study shows Kae alleviates #Arthritis in mice by balancing #Treg/#Th17 via the #miR34a/#Foxp3 axis, highlighting #therapeutic potential for #RA and #Immune #Homeostasis. #medsky
Full article here: doi.org/10.1007/s115...
#TargetDiscovery #TherapeuticTargets #DrugDevelopment
Full article here: doi.org/10.1007/s115...
#TargetDiscovery #TherapeuticTargets #DrugDevelopment
Excited to share our mini-review published in The Hematologist with Lucy Perez-Lugo and @apwiita.bsky.social ! A deep dive into surface target discovery for immunotherapy using cutting-edge technologies. Read it here: ashpublications.org/thehematolog... #Immunotherapy #Hematology #TargetDiscovery
Technology SpotlightSurface Target Discovery for Blood Cancer Immunotherapies
The tumor surface proteome, or surfaceome, is vital for tumor-microenvironment interactions and therapeutic innovation.1 Targeting cell surface proteins is
ashpublications.org
January 17, 2025 at 5:29 AM
Excited to share our mini-review published in The Hematologist with Lucy Perez-Lugo and @apwiita.bsky.social ! A deep dive into surface target discovery for immunotherapy using cutting-edge technologies. Read it here: ashpublications.org/thehematolog... #Immunotherapy #Hematology #TargetDiscovery
Across the industry the same target names keep reappearing: many programmes, one gene. Often that is shared reading, not consensus. Disease Atlas by Euretos ranks on primary biology, not citation count, so causal but quiet genes surface too. #TargetDiscovery
September 17, 2026 at 8:00 AM
Across the industry the same target names keep reappearing: many programmes, one gene. Often that is shared reading, not consensus. Disease Atlas by Euretos ranks on primary biology, not citation count, so causal but quiet genes surface too. #TargetDiscovery
Speed is only half of ease of use. The other half is defending what you found. Disease Atlas by Euretos keeps every score traceable to source: genetics, perturbation, the cell types where disease operates. The rationale is already assembled when a committee asks. #TargetDiscovery
September 10, 2026 at 7:02 AM
Speed is only half of ease of use. The other half is defending what you found. Disease Atlas by Euretos keeps every score traceable to source: genetics, perturbation, the cell types where disease operates. The rationale is already assembled when a committee asks. #TargetDiscovery
Some target questions used to need a whole project: staff it, queue it, wait weeks. Disease Atlas by Euretos does it in one session. The evidence layers arrive already integrated and resolved to cell type. You ask, follow them, leave with a defensible rationale. #TargetDiscovery
September 8, 2026 at 7:02 AM
Some target questions used to need a whole project: staff it, queue it, wait weeks. Disease Atlas by Euretos does it in one session. The evidence layers arrive already integrated and resolved to cell type. You ask, follow them, leave with a defensible rationale. #TargetDiscovery
A gene studied for decades looks better on paper than one found last year. That is bias in the evidence, not biology. Disease Atlas ranks on primary data: genetics, perturbation, single-cell expression, not papers. A candidate rises when the biology converges. #TargetDiscovery
September 7, 2026 at 7:35 AM
A gene studied for decades looks better on paper than one found last year. That is bias in the evidence, not biology. Disease Atlas ranks on primary data: genetics, perturbation, single-cell expression, not papers. A candidate rises when the biology converges. #TargetDiscovery
A ranking is only as trustworthy as the evidence under it. Disease Atlas grades confidence for every disease: many genetic loci and drug precedent earn a higher-confidence call, a long-tail disease with a handful of loci does not, and the platform says so. #TargetDiscovery
September 3, 2026 at 7:02 AM
A ranking is only as trustworthy as the evidence under it. Disease Atlas grades confidence for every disease: many genetic loci and drug precedent earn a higher-confidence call, a long-tail disease with a handful of loci does not, and the platform says so. #TargetDiscovery
The best biology is not always the crowded biology. Disease Atlas reads competition next to conviction. NOD2 in Crohn has the strongest genetic case in the disease, at the top evidence tier, and no approved drug targets it. High conviction, open field. #TargetDiscovery
August 28, 2026 at 7:02 AM
The best biology is not always the crowded biology. Disease Atlas reads competition next to conviction. NOD2 in Crohn has the strongest genetic case in the disease, at the top evidence tier, and no approved drug targets it. High conviction, open field. #TargetDiscovery
The evidence only helps if it survives the meeting. Disease Atlas builds a structured, sourced brief for a candidate from the same layers you assessed it on, ready to defend. The work shifts from assembling the argument to checking it. #TargetDiscovery
August 24, 2026 at 7:05 AM
The evidence only helps if it survives the meeting. Disease Atlas builds a structured, sourced brief for a candidate from the same layers you assessed it on, ready to defend. The work shifts from assembling the argument to checking it. #TargetDiscovery
#Targetome
AI-assisted TCM target identification integrates network pharmacology, omics data, and professional databases to pinpoint bioactive compound targets.
Details: https://www.maxapress.com/article/doi/10.48130/targetome-0026-0027
#TCM #ArtificialIntelligence #TargetDiscovery
AI-assisted TCM target identification integrates network pharmacology, omics data, and professional databases to pinpoint bioactive compound targets.
Details: https://www.maxapress.com/article/doi/10.48130/targetome-0026-0027
#TCM #ArtificialIntelligence #TargetDiscovery
August 21, 2026 at 1:01 AM
#Targetome
AI-assisted TCM target identification integrates network pharmacology, omics data, and professional databases to pinpoint bioactive compound targets.
Details: https://www.maxapress.com/article/doi/10.48130/targetome-0026-0027
#TCM #ArtificialIntelligence #TargetDiscovery
AI-assisted TCM target identification integrates network pharmacology, omics data, and professional databases to pinpoint bioactive compound targets.
Details: https://www.maxapress.com/article/doi/10.48130/targetome-0026-0027
#TCM #ArtificialIntelligence #TargetDiscovery
A high target score is only useful if you can say what is holding it up. Disease Atlas lets you open any score into its parts: genetics, perturbation, expression, network. Two targets at the same number, carried by different evidence, are not the same bet. #TargetDiscovery
August 13, 2026 at 7:14 AM
A high target score is only useful if you can say what is holding it up. Disease Atlas lets you open any score into its parts: genetics, perturbation, expression, network. Two targets at the same number, carried by different evidence, are not the same bet. #TargetDiscovery
Choosing a target is also choosing who you'll be racing. Disease Atlas puts the competitive picture beside the biology: who else is on the target, which modalities, how far along, in the same view as the causal evidence and safety. #TargetDiscovery
August 4, 2026 at 7:00 AM
Choosing a target is also choosing who you'll be racing. Disease Atlas puts the competitive picture beside the biology: who else is on the target, which modalities, how far along, in the same view as the causal evidence and safety. #TargetDiscovery
A gene doesn't cause a disease in one step. Disease Atlas lays out the chain for any candidate: gene to pathway to cellular function to phenotype to disease, each link evidence you can open. That turns a ranked candidate into something you can reason about. #TargetDiscovery
August 3, 2026 at 7:00 AM
A gene doesn't cause a disease in one step. Disease Atlas lays out the chain for any candidate: gene to pathway to cellular function to phenotype to disease, each link evidence you can open. That turns a ranked candidate into something you can reason about. #TargetDiscovery
#DiseaseOntology #KnowledgeGraph #TargetDiscovery #Bioinformatics #OpenScience #DiseaseResearch #ComputationalBiology
June 6, 2025 at 8:05 PM
📢 Today at 11:00 AM at #BioSB2025, catch Henk-Jan van den Ham’s talk: "Wisdom of the Crowd in Genomics & Target Discovery." He’ll cover Open Targets, cBioPortal, BioChatter industry vs. academia, and more. Don’t miss it! #Genomics #OpenScience #TargetDiscovery
May 20, 2025 at 7:42 AM
📢 Today at 11:00 AM at #BioSB2025, catch Henk-Jan van den Ham’s talk: "Wisdom of the Crowd in Genomics & Target Discovery." He’ll cover Open Targets, cBioPortal, BioChatter industry vs. academia, and more. Don’t miss it! #Genomics #OpenScience #TargetDiscovery
We will demo how teams use Polly KG to:
⚡ Accelerate discovery
🎯 Improve success rates
📊 Cut reporting friction
🔗 Register: bit.ly/kg_webinar
#knowledgegraphs #lifesciences #PollyKG #drugdiscovery #AI #webinar #science #TargetDiscovery #BiomedicalAI #HealthTech
⚡ Accelerate discovery
🎯 Improve success rates
📊 Cut reporting friction
🔗 Register: bit.ly/kg_webinar
#knowledgegraphs #lifesciences #PollyKG #drugdiscovery #AI #webinar #science #TargetDiscovery #BiomedicalAI #HealthTech
July 28, 2025 at 7:37 PM
We will demo how teams use Polly KG to:
⚡ Accelerate discovery
🎯 Improve success rates
📊 Cut reporting friction
🔗 Register: bit.ly/kg_webinar
#knowledgegraphs #lifesciences #PollyKG #drugdiscovery #AI #webinar #science #TargetDiscovery #BiomedicalAI #HealthTech
⚡ Accelerate discovery
🎯 Improve success rates
📊 Cut reporting friction
🔗 Register: bit.ly/kg_webinar
#knowledgegraphs #lifesciences #PollyKG #drugdiscovery #AI #webinar #science #TargetDiscovery #BiomedicalAI #HealthTech